

OBIL/BSE/34/2018-2019**14th February, 2019**

To,

The Corporate Relations Department
The Bombay Stock Exchange Ltd,
P J Towers, 1st Floor,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Ref: Scrip Code: **538019**ISIN: **INE732P01018**

Sub: Submission of Standalone Unaudited Financial Results for the quarter and Nine months ended on 31st December, 2018.

This is to inform you that the meeting of the Board of Directors was held today, 14th February, 2019 inter alia, to consider and approve the Unaudited (limited reviewed) Financial Results for the quarter and Nine months ended on 31.12.2018.

In this regard, the following documents are enclosed herewith:

- Standalone Unaudited Financial Results for the quarter and Nine months ended on 31.12.2018 - Regulation 33 - Annexure I of SEBI (LODR) Regulations, 2015.
- Limited review report signed by the Statutory Auditor

The meeting commenced at 02:00 p.m. and concluded at 03:30 p.m.

Kindly update the above in your records.

Thanking You.

For Oceanaa Biotek Industries Limited



Xavier Jeyaraj
Managing Director

Encl: As above



Statement of Standalone Unaudited Financial Results for the quarter and period ended 31.12.2018

Part I in lakhs except earnings per share and share information/data
Quarter and period ended 31/12/2018


S.No	Particulars	Three Months Ended			Nine Months Ended		Year Ended
		31st Dec' 2018	30th Sept' 2018	31st Dec' 2017	31st Dec' 2018	31st Dec' 2017	31st March' 2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenue from Operations						
I.	(a) Income from Operations	801.36	1,401.54	1,545.12	3,304.81	3,873.59	6,044.53
II.	(b) Other Income (net)	0.22	0.20	1.79	0.51	7.40	7.50
III.	Total Revenue	801.58	1,401.73	1,546.91	3,305.33	3,880.99	6,052.03
IV.	Expenses						
	a. Purchase of stock-in-trade	469.62	807.36	937.25	1,860.68	2,216.82	3,127.87
	b. Changes in inventory of finished goods	130.78	0.61	-28.54	249.33	179.38	-150.48
	c. Employee benefit expenses	37.05	68.10	44.43	168.10	121.94	213.80
	d. Finance costs	2.70	3.02	3.31	8.83	5.54	8.43
	e. Depreciation and amortisation expenses	79.00	78.92	85.49	236.81	248.21	346.41
	f. Other expenses	67.41	209.97	81.04	459.22	376.00	814.83
	Total Expenses	786.57	1,167.97	1,122.98	2,982.96	3,147.89	4,360.87
V.	Profit/(Loss) before exceptional and extraordinary items and tax (I - IV)	15.01	233.76	423.93	322.36	733.10	1,691.16
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit / (Loss) before extraordinary items and tax (V-VI)	15.01	233.76	423.93	322.36	733.10	1,691.16
VIII.	Extraordinary Item	-	-	-	-	-	-
IX.	Profit before tax (VII-VIII)	15.01	233.76	423.93	322.36	733.10	1,691.16
X.	Tax expense						
	1 Current tax	4.37	67.42	38.50	93.01	115.50	548.05
	2 Deferred tax	-2.90	-2.90	7.06	-61.15	21.18	49.44
XI.	Profit / (Loss) for the period from continuing operations (VII-VIII)	13.54	169.24	378.38	290.51	596.42	1,093.67
XII.	Other Comprehensive Income	-	-	-	-	-	-
XIII.	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-
XIV.	Tax expenses of discontinuing operations	-	-	-	-	-	-
XV.	Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
XVI.	Profit (Loss) for the period (XI+XIV)	13.54	169.24	378.38	290.51	596.42	1,093.67
XVIII.	Earnings per equity Share						
	(1) Basic	0.10	1.25	2.79	1.25	4.40	8.06
	(2) Diluted	0.10	1.25	2.79	1.25	4.40	8.06
	See accompanying notes to the financial statements.						

Notes:

- The Unaudited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 14th February, 2019
- Figures of the previous period / year are reclassified / regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the three months and half year ended as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2015.
- There were no Investors' Complaints pending / received during the period.
- All the financial numbers presented above are prepared as per the IND AS.

For & on behalf of Board of Directors

Place: Chennai
Date : 14/02/2019



T. Xavier Jeyaraj
Managing Director
DIN:06896574



Limited Review Report

To
The Board of Directors
M/s Oceanaa Biotek Industries Limited

We have reviewed the accompanying statement of standalone unaudited financial results ("The Statement") of M/s Oceanaa Biotek Industries Limited for the quarter ended 31st December, 2018 prepared by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements

) Regulations, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors of the Issuer. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (IND AS) specified under Section 133 of the Companies Act, 2013 read with relevant Rule 7 of the Companies (Accounts) Rules, 2015 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/FAC/62/2016 dated July, 05 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Chennai
Date: 14th February, 2019

For Elangovan & Co.
Chartered Accountants
Firm Regn. No. 006990S



S. Sathish Kumar
Partner
M.No: 226384

Date: 14th February, 2019

DECLARATION

M/s Elangovan & Co., Chartered Accountants, Statutory Auditors of the Company have given an unmodified opinion with respect to the Standalone Audited Financial Results for the quarter and nine months ended on 31st December, 2018.

This declaration is submitted in compliance with Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulation, 2016, as issued by SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May, 25, 2016.

For Oceanaa Biotech Industries Limited

Xavier Jeyaraj
Managing Director
Place: Chennai



For Elangovan & Co.,
Chartered Accountants
FRN: 006990S

S. Sathish Kumar
CA S Sathish Kumar
Partner
M No.: 226384



To
The Board of Directors,
No.4B-1 Eastern Portion, 4th Floor, Centre Point Appointment,
Sadhullah Street, T Nagar, Chennai 600 017,
Tamil Nadu

Dear Sir/Madam,


We hereby confirm the following in respect of the unaudited financial statements for the quarter and nine months ended on 31st December, 2018 being presented before the Board at the meeting to be held on 14th February, 2019.

- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely

Place: **Chennai**
Date: **14.02.2019**




Xavier Jeyaraj
Managing Director
DIN: 06896574